RxDoctor Payments Data

Crystal Wright

Adult Health · Arlington, TXNPI 1568887529

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,154 of the $11,589 with a category attached, or 79.0%. Sanofi accounts for 63.2% of it on its own, with 6 other manufacturers making up the rest. Among adult health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,589in general payments, 2019–2025

Across 21 payments — averaging $551.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$7K
  • TG Therapeutics, Inc.$2K
  • Genentech USA, Inc.$2K
  • Cycle Pharmaceuticals Inc$550
  • Novartis$226
  • Amgen$172
  • plus $161 from 1 others

What the payments were for

  • Consulting fees$9,15479%
  • Speaking & faculty fees$5505%
  • Travel & lodging$7617%
  • Food & beverage$1,12410%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi8$7,324
TG Therapeutics, Inc.2$1,650
Genentech USA, Inc.3$1,505
Cycle Pharmaceuticals Inc1$550
Novartis2$226
Amgen2$172
EMD Serono, Inc.3$161

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,589 in reported general payments places this provider in the 95th percentile of 933 adult health providers in Texas.

See all adult health providers in Texas

Medicare billing

Part B allowed, 2024
$30,252
Medicare patients
222
Services billed
284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab215$1,988,634
SolirisEculizumab13$691,955
VumerityDiroximel Fumarate50$457,620
CopaxoneGlatiramer Acetate52$304,037
Rebif RebidoseInterferon Beta-1a/Albumin11$133,719
Tascenso OdtFingolimod Lauryl Sulfate12$125,323
TecfideraDimethyl Fumarate12$111,295
AmpyraDalfampridine18$103,539
Teriflunomide90$103,243
GlatopaGlatiramer Acetate27$97,231
Glatiramer Acetate28$92,946
Dalfampridine ErDalfampridine115$65,415
Dimethyl Fumarate29$53,032
FingolimodFingolimod Hcl52$29,865
MyrbetriqMirabegron35$22,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Cycle Pharmaceuticals IncTascenso Odt$550$125,32312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 933 adult health providers in Texas.

Other adult health in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →